The European Medicines Agency has once again recommended to prolong the marketing suspension of Oxbryta (Voxelotor), a drug that treats sickle cell disease (SCD). The Pfizer therapy was first suspended last year, when emerging data from clinical…
The European Medicines Agency has once again recommended to prolong the marketing suspension of Oxbryta (Voxelotor), a drug that treats sickle cell disease (SCD). The Pfizer therapy was first suspended last year, when emerging data from clinical…